María Reyes B. C.
- Country
- Spain
- Department
- Oncology
Research Overview
- A Phase III, Randomized, Double-Blinded, Placebo-Controlled Study of Tiragolumab, an Anti-Tigit Antibody, in Combination with Atezolizumab Compared with Placebo in Combination with Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer
- Phase I/IIa Study of Inhaled CIS-DPI as Adjunctive Therapy in Stage IV Non-Small Cell Lung Cancer Patients
- Non-Inferiority Study of Pembrolizumab Maintenance Therapy at Standard vs. Reduced Dose in Metastatic Non-Squamous Lung Cancer
Data & Insights
Has run more than one trial at 477 of 789 partner sites.
Specializations
Non-Small Cell Lung Cancer
Specializes in investigating innovative treatments for non-squamous and squamous NSCLC across various disease stages, with particular focus on targeted therapies and immunotherapy combinations.
- Early-stage NSCLC management
- Metastatic NSCLC treatment
- EGFR mutation-positive NSCLC
Conducts research on perioperative therapy approaches and novel drug combinations for advanced disease states.
Targeted Therapies
Investigates precision medicine approaches targeting specific molecular alterations in lung cancer, including KRAS G12C mutations and EGFR mutations.
- Novel EGFR inhibitors
- KRAS-targeted agents
- Combination strategies
Focuses on developing personalized treatment approaches based on specific genetic markers.
Immunotherapy Research
Leads studies on immune checkpoint inhibitors and their combinations with conventional therapies in lung cancer treatment.
- PD-L1 targeted therapies
- Novel immunotherapy combinations
- Biomarker-driven approaches
Evaluates innovative immunotherapy strategies across different lung cancer subtypes and stages.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.